Schedule an Appointment! (214) 556-0590

Logo

Ioannis Alexander Avramis, MD

Using his fellowship training in spinal surgery for adult and pediatric patients, Ioannis Alexander Avramis, MD, board-certified orthopedic surgeon, focuses on the comprehensive treatment of spinal deformity of both patient populations. Dr. Avramis is research director of the Medical City Scoliosis & Advanced Spine Center through which he endeavors to develop innovative treatments for spine conditions. In the past, he has also served as research director of the Baylor Scott and White Scoliosis Center – Plano.

Dr. Avramis was born in Houston and raised in southern California. He earned his bachelor’s degree from UCLA, was inducted into Phi Beta Kappa and graduated with honors summa cum laude. Medical school studies were completed at UC Davis in Sacramento, California, followed by an orthopedic surgery residency at the University of Southern California and Los Angeles County Hospital. Dr. Avramis has received additional specialized training in adult and pediatric spinal surgery during his fellowship at UC Davis Medical Center and Shriners Hospital for Children-Northern California.

Dr. Avramis is dedicated to advancing the field of spinal surgery through research, publication and membership in various societies which include the American Academy of Orthopaedic Surgeon, North American Spine Society and Scoliosis Research Society. He has contributed to more than thirty medical publications and spine textbook chapters, and holds a medical patent. In addition to the book chapters and research projects for which he serves as principal investigator, Dr. Avramis is interested in the development of instruments and techniques that allow patients to have a more successful and less painful surgical experience.

Curriculum Vitae

Current Title and Affiliations

Physician, Southwest Scoliosis Institute Medical Director of Research, Medical City Scoliosis and Advanced Spine Center

Education

August 2002 – June 2006 University of California Davis School of Medicine Doctor of Medicine August 1998 – March 2002 University of California Los Angeles Bachelor’s of Science – Biology – Summa cum Laude

Post-Graduate Training

August 2011 – July 2012 University of California Davis Medical Center Fellowship – Pediatric & Adult Spine Surgery July 2007 – June 2011 Los Angeles County + University of Southern California Residency – Orthopaedic Surgery June 2006 – June 2007 Los Angeles County + University of Southern California Internship

Licensures / Board Certifications

August 2016 – 2026 Certified, American Board of Orthopaedic Surgeons Texas Medical Board State License California Medical Board State License

Society Memberships

American Academy of Orthopedic Surgeons North American Spine Society Eagle Scout The National Society of Collegiate Scholars Gold Key Honor Society Phi Beta Kappa Member

Research

Childrens Hospital Los Angeles, Research Student 1995-2010 Summary of Research: Pre-clinical and clinical research investigating cytotoxic chemotherapy agents alone and in combination against hematological cancers, mostly ALL Leukemia, in Phase I, IIa and IIb trials. Investigation in pre-clinical and clinical research examining the effect of Vascular Endothelial Growth Factor (VEGF) in human refractory leukemia cells and in human brain tumor cells (glioblastoma). UCLA, Department of Neurobiology, August 1999- June 2000 Summary of Research: Surgical removal of hippocampus from 3-day old mice and culture for neurotransmitter identification. Patch clamping of cells to test membrane potential variations. UCLA, Deparment of Chemistry and Biochemistry, May 2001- July 2001 Summary of Research: Creation of bacculovirus vector containing Groucho mutants and expression in insect cells in order to characterize the binding interaction of Groucho. USC, Department of Orthopaedic Surgery, May 2008- present Summary of Research: Comparison of the cross sectional area of the supraspinatus fossa on MRI and Radiographs of patients with supraspinatus impingement to a control group. Evaluation of shoulder radiographs value in determining supraspinatus impingement and stenosis of the supraspinatus fossa. CHLA-USC, Department of Orthopaedic Surgery, August 2008- 2011 Summary of Research: Case series of open reduction internal fixation of sacral facet fractures in high level pediatric athletes. UC Davis, Department of Orthopaedic Surgery, August 2011- present Summary of Research: Determination of factors leading to catastrophic failure of laminoplasty.

Publications

Avramis, I.A., Kwock, R., and Avramis, V. I. Taxotere and vincristine inhibit the secretion of the angiogenesis-inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res. 21:2281-2286, 2001. Avramis, V. I., Kwock, R., Avramis, I. A., Cohen, L.J., and Inderlied, C. Synergistic Antiviral Effect of PEG-Asparaginase (ONCASPAR) With Protease Inhibitor Alone and in Combination with RT Inhibitors Against HIV-1 Infected T-cells: A Model of HIV-1-Induced T-cell Lymphoma. IN VIVO, 15:1-10, 2001. Majlessipour F, Avramis IA, Kwock, R, Weinberg, KI, and Avramis VI. The Combination Regimen of Idarubicin and Taxotere is Effective Against Human Drug-Resistant Leukemic Cell Lines. Anticancer Res., 22(3):1361-1368, 2002. Avramis IA, Christodoulopoulos G, Suzuki A, Laug WE, Gonzalez-Gomez I, McNamara G, Sausville EA, Avramis VI. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother. Pharmacol., Dec;50(6):479-489, 2002. Avramis IA, Laug WE, Sausville EA, and Avramis VI. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (Adaphostin) and/or STI571 (Imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother. Pharmacol., 52(4):307-318, 2003. Panosyan, E. H., Seibel, N. L., Gaynon, P.S., Sather, H., Avramis, I.A., Martin-Aragon, S., Franklin, J., Nachman, J., Ettinger, L., La, M., Steinherz, P., Cohen, L.J., Siegel, S.E., and Avramis, V. I. Asparaginase Antibody and Asparaginase Activity in Children with Higher Risk Acute Lymphoblastic Leukemia: Children’s Cancer Group Study CCG-1961. J Ped Hema Oncol, 26:217-226, 2004. Grigorian R. S., Panosyan E. H., Seibel, N. L., Gaynon, P. S., Avramis, I. A., and Avramis, V. I. Changes in amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In vivo, 18:107-112, 2004. Panosyan, E. H., Grigorian, R.S., Avramis, I.A., Seibel, N. L., Gaynon, P.S., Fingert, H., Siegel, S.E., and Avramis, V. I. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res.: 24: 1121-1126, 2004. Ioannis A. Avramis, Eduard H. Panosyan, Fred Dorey, John S. Holcenberg, Stuart E. Siegel, and Vassilios I. Avramis. Vascular endothelial growth factor (VEGF) serum levels predict treatment outcome in pediatirc patients with standard risk acute lymphoblastic leukemia (SR ALL): a case control study (Children’s Cancer group study, CCG-1962). J Clin Cancer Research, 12(23): 6978-84, 2006. Skaggs DL, Avramis I, Myung K, Weiss J. Sacral Facet Fractures in Elite Athletes. Spine 15;37(8):E514-517, 2012.

Abstracts

Ioannis A. Avramis, Garyfallia Christodoulopoulos, Richard Kwock, Edward A. Sausville, and Vassilios I. Avramis. NSC 680410 AND NSC 642492: Novel Antileukemic Agents with Activity in p53-null Leukemias In Vitro. Proc. Am. Assoc. for Cancer Res., 42:189, Abstr # 1015, 2001. Garyfallia Christodoulopoulos, Richard Kwock, Ioannis A. Avramis, Fae Majlessipour and Vassilios I. Avramis. Chemosensitivity Studies in a Human Leukemia Model Resistant to Ara-C plus Asparaginase (ASNase). Proc. Am. Assoc. for Cancer Res., 42:204, Abstr # 1095, 2001. Avramis, I.A., Kwock, R., and Avramis, V.I. Taxotere (TXR) & Vincristine (VCR) Inhibit Secretion of Vascular Endothelial Growth Factor (VEGF) by Human Leukemia T-cell Lines. Proc. Am. Soc. Clin Oncol. (ASCO), 20:371a, Abstr. # 1481, 2001. Christodoulopoulos, G., Avramis, I.A., Suzuki, A., Kwock, R., Laug, W.E., Sausville, E.A., and Avramis, V.I. In Vitro and In Vivo Anticancer Evaluations of Two Novel Tyrosine Kinase Inhibitors NSC 680410 and NSC 642492. Anticancer Research, 21:1580, Abstr., #109, 2001 Avramis, V.I., Panosyan, E., Avramis, I. A., Gaynon, P., Sather, H., Ettinger, L., Cohen, L., Seibel, N. Asparaginase (ASNase) Activity, Anti-ASNase Antibody (Ab), and Amino Acid Deamination in Children With Higher Risk Acute Lymphoblastic Leukemia (HR ALL) (CCG-1961). Oral presentation at the 3rd Biennial Hannover Symposium on Childhood Leukemia, Hanover, Germany, February 2002. Avramis, I.A., Christodoulopoulos, G., Suzuki, A., Laug, W.E., Gonzalez, I., Erdreich-Epstein, A., McNamara, G., Sausville, E. A., and Avramis, V.I. In Vitro and In Vivo Evaluations of the Tyrosine Kinase Inhibitor NSC680410 Against Human Leukemia and Glioblastoma Lines. Proc. Am. Assoc. for Cancer Res., 43:336, Abstr # 1666, 2002. Avramis, I.A., Sausville, E. A.,and Avramis V.I. Combination studies between NSC680410 and anti-leukemic cytotoxic drugs in human leukemia lines. Proc. Am. Assoc. for Cancer Res., 43:338, Abstr # 1678, 2002. Avramis, V. I., Panosyan E., Avramis, I.A., Martin-Aragon, S., Gaynon, P., Sather, H., Ettinger, L.J., Cohen, L., and Seibel, N. Anti-asparaginase (ASNase) antibody (Ab) and ASNase activity in children with higher risk acute lymphoblastic leukemia (HR ALL) (CCG-1961). Proc. Am. Soc. Clin. Oncol., 21:399a, Abstr. # 1592, 2002. Panosyan, E., Avramis, I.A., Seibel, N.L., Grigorian, R., Gaynon, P.S., Sather, H., Siegel, S. E., and Avramis, V.I. Glutamine (Gln) deamination by asparaginases (ASNases) in children with higher risk acute lymphoblastic leukemia (HR ALL), (CCG-1961 study). Blood, 100:759a, Abstr# 3006, 2002. Panosyan, E., Avramis, I.A., Seibel, N.L., Grigorian, R., Gaynon, P.S., Sather, H., Siegel, S. E., and Avramis, V.I. Asparagine (Asn) deamination in children with higher risk acute lymphoblastic leukemia (HR ALL) at lower asparaginases (ASNase) activity levels (CCG-1961 study). Blood, 100:760a, Abstr# 3007, 2002. Avramis, I.A., Panosyan, E.H., Grigoryan, R.S., Sather, H., Gaynon, P.S., Siegel, S.E., Holcenberg, J.S., Avramis, V.I. Correlation of vascular endothelial growth factor (VEGF) serum levels and outcome in SR ALL patients (pts).: A case-control study (CG-1962). Proc. Am Soc Clin Oncol. 22: p.808, Abstr. #3247, Chicago, Ill, 2003. Panosyan, E.H., Grigoryan, R.S., Avramis, I.A., Seibel, N.L., Gaynon, P.S., Siegel, S.E., and Avramis, V.I. Deamination of glutamine (Gln) is a prerequisite for optimal asparagine (Asn) deamination by asparaginases (ASNase) in vivo (CCG-1961). Proc. Am Soc Clin Oncol. 22:p.808, Abstr. #3246, Chicago, Ill, 2003. Grigoryan, R.S., Panosyan, E.H., Avramis, I.A., Seibel, N.L., Gaynon, P.S., Siegel, S.E., and Avramis, V.I. Correlation of 3 essential and 4 non-essential amino acid (AA) levels with asparaginase (ASNase) concentrations in serum of higher risk acute lymphoblastic leukemia (HR ALL) pediatric patients (pts) after chemotherapy (Tx) (CCG-1961). Proc. Am Soc Clin Oncol. 22:p.812, Abstr. #3265, Chicago, Ill, 2003. Panosyan, E. H., Grigorian, R.S., Avramis, I.A., Jaques, J.D., Seibel, N.L., Ettinger, L.J., Gaynon, P.S., Siegel, S.E., Fingert, H.J., and Avramis, V.I. Asparaginase (ASNase) activity, amino acid serum concentrations, and clinical outcome in pediatric patients with higher risk acute lymphoblastic leukemia (HR ALL): A report from CCG-1961. Blood, 102(11):p378a, Abstr.#1374, 2003. Panosyan, E.H., Seibel, N.L., Grigorian, R.S., Avramis, I.A., Jaques, J.D., Ettinger L.J., Gaynon, P.S., Sather, H.N., Franklin, J., Fu, C.H., Siegel, S.E., Fingert, H.J., and Avramis, V.I. Pharmacokinetics and pharmacodynamics of three asparaginases in pediatric patients with higher risk acute lymphoblastic leukemia: A report from CCG-1961. Blood 104 (11): p751a, Abstr.#2745, San Diego, CA, 2004. Arce, F.J., Seibel, N., Gaynon, P. S., Tiwari, P. N., Avramis, I. A., Ettinger, L. J., Sather, H. N., Franklin, J., Fu, C., Siegel, S. E., and Avramis, V.I. Pharmacokinetics and Pharmacodynamics of Asparaginases in antibody-negative pediatric patients with higher risk acute lymphoblastic leukemia (ALL): A report from CCG-1961. Proc. Am. Assoc. Clin Oncol. 24: p508, Abstr.# 9027, 2006. Avramis, I. A. E. H. Panosyan, F. Dorey, J. S. Holcenberg, V. I. Avramis. Vascular endothelial growth factor (VEGF-A) serum levels in standard risk ALL pediatric patients (CCG-1962 study). Proc. Am. Assoc. Clin Oncol. 24: p508, Abstr.# 9026, 2006.

Patents

Patent Inventor for Patent Application for Novartis Pharma, AG, on Anti-angiogenesis, Case # 4-32344A/CHL. All rights belong to Novartis Pharma, AG. This patent application is based on the following publications: Avramis I. A., Christodoulopoulos G., Suzuki A., Laug W.E., Gonzalez-Gomez I., McNamara G., Sausville E.A., Avramis V.I. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother. Pharmacol., 50(6):479-489, 2002. Avramis, I. A., Laug, W.E., Sausville, E.A., and Avramis, V. I. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (Adaphostin) and STI571 (Imatinib Mesylate, GLEEVEC) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother. Pharmacol., 52(4):307-318, 2003.